Association between pioglitazone and urothelial bladder cancer.
The U.S. Food and Drug Administration and the European Medicines Agency have recently informed the public of a potential impact of pioglitazone (Actos) use on bladder cancer incidence. These recommendations are based on 2 recent large published cohort studies indicating a possible association between pioglitazone use and bladder cancer development. Currently, there is no urology literature on this subject. We present the current literature reporting the association between pioglitazone and bladder cancer.